Setmelanotide vs HGH Fragment 176-191
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Setmelanotide
Setmelanotide (Imcivree) is an FDA-approved MC4R agonist for chronic weight management in patients with obesity due to specific genetic conditions (POMC, PCSK1, or LEPR deficiency).
Full details →HGH Fragment 176-191
HGH Fragment 176-191 is the fat-reducing portion of the growth hormone molecule. Unlike AOD-9604 (which has an additional tyrosine), this is the exact fragment of HGH responsible for lipolytic effects.
Full details →Side-by-Side Comparison
| Aspect | Setmelanotide | HGH Fragment 176-191 |
|---|---|---|
| Mechanism | Selective agonist of melanocortin 4 receptors (MC4R) in the hypothalamus, restoring the satiety signaling pathway that is disrupted in certain genetic obesity syndromes. | Mimics the lipolytic region of growth hormone, stimulating fat breakdown and inhibiting lipogenesis without affecting blood sugar or promoting growth. Works independently of GH receptors. |
| Typical Dosage | Adults: Start 2mg daily, titrate based on tolerability up to 3mg daily. Pediatrics (6+): Weight-based dosing starting at 1mg daily. | Typical dosing: 250-500mcg daily, often split into 2-3 doses. Usually administered on empty stomach, often with fasted cardio. |
| Administration | Subcutaneous injection once daily. Requires genetic testing to confirm eligible mutations before prescribing. | Subcutaneous injection. Best results when used fasted and combined with exercise. Avoid eating for 30 minutes post-injection. |
| Side Effects | Injection site reactions, skin hyperpigmentation, spontaneous penile erections, depression, and suicidal ideation (boxed warning). GI effects less common than GLP-1s. | Generally well-tolerated. May cause injection site irritation, temporary lethargy, or headache. Does not affect blood glucose significantly. |
| Best For |
What They Have in Common
Both Setmelanotide and HGH Fragment 176-191 are commonly used for: